Clascoterone 5% (Breezula) is one of the most anticipated hair loss treatments in development - a topical androgen receptor antagonist that blocks DHT at the follicle without lowering systemic hormone levels. Here’s what the clinical data actually shows, how it compares to other topical anti-androgens like pyrilutamide (KX-826), and what patients should realistically expect.
Clascoterone is a topical androgen receptor (AR) antagonist developed by Cassiopea, later acquired by Cosmo Pharmaceuticals. It works by competing directly with dihydrotestosterone (DHT) at the androgen receptor in the hair follicle - essentially filling the lock with a dummy key so that when DHT shows up, the receptor is already occupied and cannot trigger the miniaturization process that drives androgenetic alopecia (AGA).
What makes clascoterone especially interesting is that it is designed to work locally. Once it has done its job in the skin, it breaks down into a nearly inactive metabolite called cortexolone. The design intent is minimal systemic exposure, though phase 1 data for the AGA solution formulation did show measurable systemic concentration and accumulation. That does not mean the drug is unsafe - a separate phase 1 QT study found no clinically relevant cardiac effect - but “essentially none reaches the blood” would be stronger than the evidence supports. This local-first design is what separates it from oral 5-alpha reductase inhibitors like finasteride or dutasteride, which lower DHT systemically.
The 1% formulation is already FDA-approved under the brand name Winlevi for acne (also an androgen-driven condition). The 5% concentration, being developed under the name Breezula, is what the hair loss community has been waiting for. Cosmo reported positive Phase 3 top line results in December 2025, with a required 12-month safety follow-up expected in spring 2026 before regulatory filings in the US and EU. First approvals could come by mid-2027, though the timeline has slipped before. Breezula has been under development by multiple companies for nearly two decades.
The main driver of androgenetic alopecia is DHT binding to androgen receptors on follicle cells, triggering miniaturization. Your hair gets thinner, weaker, and more miniaturized with every cycle until the follicle is no longer producing visible hair.
Clascoterone is a competitive antagonist. It occupies the androgen receptor before DHT can get there. The follicle is shielded from the androgen signal without reducing circulating DHT levels. This is fundamentally different from 5-alpha reductase inhibitors (finasteride, dutasteride), which reduce DHT production system-wide.
This local mechanism is why clascoterone is often described as offering “DHT protection without systemic hormonal disruption.” Cosmo’s Phase 3 top line reported that treatment-emergent adverse events were similar to the placebo, with an overall favorable tolerability profile.
That said, even the 1% acne-approved formulation has shown HPA axis suppression in some patients, meaning some measurable systemic hormonal signal is getting through even at the lower dose. At the 5% scalp dose, the exposure question becomes more relevant - which is exactly why the 12-month safety follow-up data matters.
Cosmo reported positive top line results from two Phase 3 trials (the SCALP studies) with 1,465 patients total, showing statistically significant improvements over placebo. That is a legitimate milestone - but the headline numbers require some context.
One trial reported a 539% hair count improvement compared to placebo. The other showed 168%. Those are relative figures, and relative figures can be deeply deceptive. If the placebo group gained 2.5 hairs per cm² and the clascoterone group gained 14, that is technically over five times more. The math checks out. But the absolute gain - roughly 14 hairs per cm² - is right in the same range as what topical minoxidil 5% delivers (roughly 13-18 hairs/cm² over 6-12 months).
Cosmo themselves acknowledged this. Their CEO stated the gap between the two study numbers was driven entirely by baseline hair counts between the two study populations, not by a difference in drug performance. They have said full absolute hair count and hair width data will be presented at a medical conference and in a peer-reviewed journal.
Until that data lands, a tentative read is that clascoterone 5% may be in a similar range to minoxidil on raw regrowth, with a potentially better side-effect profile. But without the full absolute hair-count dataset, a clean apples-to-apples comparison is not yet possible.
The bigger gap in the evidence is long-term durability. Most clascoterone trials run 6-12 months. We do not have 3-year, 5-year, or 10-year efficacy data.
We do not know if its protective effect plateaus or weakens over time - and there are specific concerns about whether Breezula shows efficacy degradation in a way that other topical anti-androgens may not. That is still an open question.
This is where clascoterone has generated the most excitement. The design intent is local metabolism: it breaks down into cortexolone in the skin before reaching the bloodstream. In Phase 3, Cosmo reported that treatment-emergent adverse events were similar to the placebo and overall tolerability was favorable.
But the nuance matters. Even the 1% acne formulation has demonstrated HPA axis suppression in a subset of patients - meaning some systemic hormonal signal is getting through. At the 5% scalp dose applied daily, the exposure question becomes more relevant. Claiming “zero systemic effects whatsoever” is a stronger claim than the current evidence fully supports. The 12-month safety follow-up, expected in spring 2026, will be the real test.
On the local side, anecdotal reports from real-world users of compounded clascoterone describe an adaptation period of several months - sometimes up to eight months - of irritation, itching, or other local effects before things settle. The FDA label for 1% clascoterone lists local reactions including erythema, pruritus, scaling/dryness, and stinging/burning. Clinical trials for the 5% formulation reported only mild local irritation, but community experience suggests the adjustment window may be longer than trial data alone would indicate. This is anecdotal and should be weighed accordingly.
Bottom line: clascoterone looks meaningfully cleaner on side effects than finasteride or dutasteride, but the full safety picture is not complete yet.
Clascoterone is not the only topical anti-androgen in development. Pyrilutamide (KX-826), developed by Kintor Pharma, is arguably the more potent compound. Based on in vitro binding affinity data and community reports, pyrilutamide appears to be a stronger AR antagonist.
Kintor’s March 2026 pivotal Phase III update reported +15.33 hairs/cm² from baseline at 24 weeks for the 1.0% BID group. A separate 52-week long-term safety study described positive efficacy signals and responder rates, but did not report that same figure. It is also worth noting an earlier 24-week Phase III trial failed to beat placebo, suggesting pyrilutamide may be a slow-build treatment.
If pyrilutamide is more potent than clascoterone but still underperforms finasteride, that gives you a realistic sense of where topical AR antagonists sit in the overall hierarchy.
The trade-off: pyrilutamide is not approved anywhere yet, and many users in the hair loss community have been self-sourcing it through research chemical suppliers. It comes without the safety oversight of an approved drug, and long-term risks are not fully understood.
Also from Kintor, GT20029 uses PROTAC technology to not just block androgen receptors but degrade them entirely. Early Phase II data has tested low-frequency dosing as infrequently as twice weekly, with promising signals.
It is early-stage, but it represents where the field is heading - from blocking receptors to eliminating them at the follicle level.
Clascoterone’s real advantages are not raw potency. They are its FDA approval track record (via Winlevi), its existing safety data from the acne indication, and the expectation that it will eventually be available through mainstream pharmacy channels.
For patients who want a topical anti-androgen from a regulated, commercially available product, clascoterone is likely the first one that will actually be on the shelf.
Not every hair loss patient needs a topical anti-androgen. Understanding where clascoterone fits in a protocol matters more than whether it “works” in isolation.
Clascoterone makes the most sense for men or women with confirmed androgenetic alopecia who want to target the root cause - androgen-driven miniaturization - without the systemic hormonal effects of finasteride or dutasteride. If finasteride’s side-effect profile concerns you, or you tried it and had to stop, clascoterone offers DHT protection without the systemic hormonal disruption that comes with oral 5-alpha reductase inhibitors.
It also makes sense as an add-on. Minoxidil stimulates growth. Clascoterone blocks damage. They work through completely independent pathways - no pharmacological conflict, no cancellation. They complement each other. While we do not yet have formal combination trial data, the logic is sound, and a minoxidil plus clascoterone protocol is a very reasonable direction for a topical regimen once it is available.
Where clascoterone is less useful: if your hair loss is not androgen-driven. Telogen effluvium, diffuse thinning from stress, nutritional deficiencies - these will not respond to an AR antagonist. A proper diagnosis from a dermatologist is always step one.
When clascoterone 5% does launch, expect it to be expensive. Cosmo has not publicly disclosed a launch price for Breezula, but given the pricing of Winlevi (the 1% acne formulation) and the cost structure of branded topical dermatologics, industry observers expect it to carry a significant premium. That is a meaningful factor, especially since affordable alternatives like compounded topical dutasteride are already delivering results for a fraction of what branded topicals typically cost.
The current estimated timeline puts FDA approval around mid-2027 at the earliest. Given that Breezula has been in development for nearly two decades with multiple ownership changes, it is worth building in some realistic skepticism before rearranging your protocol around a launch date.
The treatments that are available today - minoxidil, finasteride, dutasteride, microneedling - remain the evidence-backed foundation of any serious hair loss protocol. Hair loss is progressive. Every month without a protocol means losing ground that is harder to recover.
Start with what is available now, and when clascoterone launches, talk to your dermatologist about adding it in.
Is clascoterone FDA-approved for hair loss?
Not yet. Clascoterone 1% is FDA-approved for acne under the brand name Winlevi. The 5% formulation (Breezula) for androgenetic alopecia reported positive Phase 3 topline results in December 2025, with a 12-month safety follow-up expected in spring 2026 before regulatory filings. A potential launch could come around mid-2027.
Is clascoterone better than finasteride?
They work differently. Finasteride lowers DHT systemically by inhibiting 5-alpha reductase. Clascoterone blocks DHT at the receptor level locally. On raw hair regrowth numbers, finasteride still appears to deliver more (~20+ hairs/cm² vs. ~14 for clascoterone). Clascoterone’s advantage is its potentially cleaner side-effect profile. For many patients, the two could eventually be used together.
Can I use clascoterone with minoxidil?
There is no pharmacological reason you could not. Minoxidil promotes growth via potassium channel activation; clascoterone blocks androgen-driven damage. They target different parts of the hair loss equation. Formal combination trial data is not available yet, but the mechanistic logic supports using them together.
What about pyrilutamide - is that better?
Pyrilutamide (KX-826) appears to be a stronger AR antagonist in vitro, and Kintor Pharma’s pivotal Phase III data showed +15.33 hairs/cm² from baseline at 24 weeks for the highest dose. However, it is not approved anywhere, has no long-term safety data from regulatory trials, and an earlier 24-week trial failed to beat placebo. Clascoterone has the regulatory advantage and a clearer path to market.
Cosmo Pharmaceuticals. Clascoterone 5% (Breezula) Phase 3 clinical trial results. 2025.
Kintor Pharmaceutical. KX-826 Phase III pivotal trial top line results. March 2026.
Olsen EA, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385.
Kaufman KD, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589.
Clascoterone 5% (Breezula) is one of the most anticipated hair loss treatments in development - a topical androgen receptor antagonist that blocks DHT at the follicle without lowering systemic hormone levels. Here’s what the clinical data actually shows, how it compares to other topical anti-androgens like pyrilutamide (KX-826), and what patients should realistically expect.
Clascoterone is a topical androgen receptor (AR) antagonist developed by Cassiopea, later acquired by Cosmo Pharmaceuticals. It works by competing directly with dihydrotestosterone (DHT) at the androgen receptor in the hair follicle - essentially filling the lock with a dummy key so that when DHT shows up, the receptor is already occupied and cannot trigger the miniaturization process that drives androgenetic alopecia (AGA).
What makes clascoterone especially interesting is that it is designed to work locally. Once it has done its job in the skin, it breaks down into a nearly inactive metabolite called cortexolone. The design intent is minimal systemic exposure, though phase 1 data for the AGA solution formulation did show measurable systemic concentration and accumulation. That does not mean the drug is unsafe - a separate phase 1 QT study found no clinically relevant cardiac effect - but “essentially none reaches the blood” would be stronger than the evidence supports. This local-first design is what separates it from oral 5-alpha reductase inhibitors like finasteride or dutasteride, which lower DHT systemically.
The 1% formulation is already FDA-approved under the brand name Winlevi for acne (also an androgen-driven condition). The 5% concentration, being developed under the name Breezula, is what the hair loss community has been waiting for. Cosmo reported positive Phase 3 top line results in December 2025, with a required 12-month safety follow-up expected in spring 2026 before regulatory filings in the US and EU. First approvals could come by mid-2027, though the timeline has slipped before. Breezula has been under development by multiple companies for nearly two decades.
The main driver of androgenetic alopecia is DHT binding to androgen receptors on follicle cells, triggering miniaturization. Your hair gets thinner, weaker, and more miniaturized with every cycle until the follicle is no longer producing visible hair.
Clascoterone is a competitive antagonist. It occupies the androgen receptor before DHT can get there. The follicle is shielded from the androgen signal without reducing circulating DHT levels. This is fundamentally different from 5-alpha reductase inhibitors (finasteride, dutasteride), which reduce DHT production system-wide.
This local mechanism is why clascoterone is often described as offering “DHT protection without systemic hormonal disruption.” Cosmo’s Phase 3 top line reported that treatment-emergent adverse events were similar to the placebo, with an overall favorable tolerability profile.
That said, even the 1% acne-approved formulation has shown HPA axis suppression in some patients, meaning some measurable systemic hormonal signal is getting through even at the lower dose. At the 5% scalp dose, the exposure question becomes more relevant - which is exactly why the 12-month safety follow-up data matters.
Cosmo reported positive top line results from two Phase 3 trials (the SCALP studies) with 1,465 patients total, showing statistically significant improvements over placebo. That is a legitimate milestone - but the headline numbers require some context.
One trial reported a 539% hair count improvement compared to placebo. The other showed 168%. Those are relative figures, and relative figures can be deeply deceptive. If the placebo group gained 2.5 hairs per cm² and the clascoterone group gained 14, that is technically over five times more. The math checks out. But the absolute gain - roughly 14 hairs per cm² - is right in the same range as what topical minoxidil 5% delivers (roughly 13-18 hairs/cm² over 6-12 months).
Cosmo themselves acknowledged this. Their CEO stated the gap between the two study numbers was driven entirely by baseline hair counts between the two study populations, not by a difference in drug performance. They have said full absolute hair count and hair width data will be presented at a medical conference and in a peer-reviewed journal.
Until that data lands, a tentative read is that clascoterone 5% may be in a similar range to minoxidil on raw regrowth, with a potentially better side-effect profile. But without the full absolute hair-count dataset, a clean apples-to-apples comparison is not yet possible.
The bigger gap in the evidence is long-term durability. Most clascoterone trials run 6-12 months. We do not have 3-year, 5-year, or 10-year efficacy data.
We do not know if its protective effect plateaus or weakens over time - and there are specific concerns about whether Breezula shows efficacy degradation in a way that other topical anti-androgens may not. That is still an open question.
This is where clascoterone has generated the most excitement. The design intent is local metabolism: it breaks down into cortexolone in the skin before reaching the bloodstream. In Phase 3, Cosmo reported that treatment-emergent adverse events were similar to the placebo and overall tolerability was favorable.
But the nuance matters. Even the 1% acne formulation has demonstrated HPA axis suppression in a subset of patients - meaning some systemic hormonal signal is getting through. At the 5% scalp dose applied daily, the exposure question becomes more relevant. Claiming “zero systemic effects whatsoever” is a stronger claim than the current evidence fully supports. The 12-month safety follow-up, expected in spring 2026, will be the real test.
On the local side, anecdotal reports from real-world users of compounded clascoterone describe an adaptation period of several months - sometimes up to eight months - of irritation, itching, or other local effects before things settle. The FDA label for 1% clascoterone lists local reactions including erythema, pruritus, scaling/dryness, and stinging/burning. Clinical trials for the 5% formulation reported only mild local irritation, but community experience suggests the adjustment window may be longer than trial data alone would indicate. This is anecdotal and should be weighed accordingly.
Bottom line: clascoterone looks meaningfully cleaner on side effects than finasteride or dutasteride, but the full safety picture is not complete yet.
Clascoterone is not the only topical anti-androgen in development. Pyrilutamide (KX-826), developed by Kintor Pharma, is arguably the more potent compound. Based on in vitro binding affinity data and community reports, pyrilutamide appears to be a stronger AR antagonist.
Kintor’s March 2026 pivotal Phase III update reported +15.33 hairs/cm² from baseline at 24 weeks for the 1.0% BID group. A separate 52-week long-term safety study described positive efficacy signals and responder rates, but did not report that same figure. It is also worth noting an earlier 24-week Phase III trial failed to beat placebo, suggesting pyrilutamide may be a slow-build treatment.
If pyrilutamide is more potent than clascoterone but still underperforms finasteride, that gives you a realistic sense of where topical AR antagonists sit in the overall hierarchy.
The trade-off: pyrilutamide is not approved anywhere yet, and many users in the hair loss community have been self-sourcing it through research chemical suppliers. It comes without the safety oversight of an approved drug, and long-term risks are not fully understood.
Also from Kintor, GT20029 uses PROTAC technology to not just block androgen receptors but degrade them entirely. Early Phase II data has tested low-frequency dosing as infrequently as twice weekly, with promising signals.
It is early-stage, but it represents where the field is heading - from blocking receptors to eliminating them at the follicle level.
Clascoterone’s real advantages are not raw potency. They are its FDA approval track record (via Winlevi), its existing safety data from the acne indication, and the expectation that it will eventually be available through mainstream pharmacy channels.
For patients who want a topical anti-androgen from a regulated, commercially available product, clascoterone is likely the first one that will actually be on the shelf.
Not every hair loss patient needs a topical anti-androgen. Understanding where clascoterone fits in a protocol matters more than whether it “works” in isolation.
Clascoterone makes the most sense for men or women with confirmed androgenetic alopecia who want to target the root cause - androgen-driven miniaturization - without the systemic hormonal effects of finasteride or dutasteride. If finasteride’s side-effect profile concerns you, or you tried it and had to stop, clascoterone offers DHT protection without the systemic hormonal disruption that comes with oral 5-alpha reductase inhibitors.
It also makes sense as an add-on. Minoxidil stimulates growth. Clascoterone blocks damage. They work through completely independent pathways - no pharmacological conflict, no cancellation. They complement each other. While we do not yet have formal combination trial data, the logic is sound, and a minoxidil plus clascoterone protocol is a very reasonable direction for a topical regimen once it is available.
Where clascoterone is less useful: if your hair loss is not androgen-driven. Telogen effluvium, diffuse thinning from stress, nutritional deficiencies - these will not respond to an AR antagonist. A proper diagnosis from a dermatologist is always step one.
When clascoterone 5% does launch, expect it to be expensive. Cosmo has not publicly disclosed a launch price for Breezula, but given the pricing of Winlevi (the 1% acne formulation) and the cost structure of branded topical dermatologics, industry observers expect it to carry a significant premium. That is a meaningful factor, especially since affordable alternatives like compounded topical dutasteride are already delivering results for a fraction of what branded topicals typically cost.
The current estimated timeline puts FDA approval around mid-2027 at the earliest. Given that Breezula has been in development for nearly two decades with multiple ownership changes, it is worth building in some realistic skepticism before rearranging your protocol around a launch date.
The treatments that are available today - minoxidil, finasteride, dutasteride, microneedling - remain the evidence-backed foundation of any serious hair loss protocol. Hair loss is progressive. Every month without a protocol means losing ground that is harder to recover.
Start with what is available now, and when clascoterone launches, talk to your dermatologist about adding it in.
Is clascoterone FDA-approved for hair loss?
Not yet. Clascoterone 1% is FDA-approved for acne under the brand name Winlevi. The 5% formulation (Breezula) for androgenetic alopecia reported positive Phase 3 topline results in December 2025, with a 12-month safety follow-up expected in spring 2026 before regulatory filings. A potential launch could come around mid-2027.
Is clascoterone better than finasteride?
They work differently. Finasteride lowers DHT systemically by inhibiting 5-alpha reductase. Clascoterone blocks DHT at the receptor level locally. On raw hair regrowth numbers, finasteride still appears to deliver more (~20+ hairs/cm² vs. ~14 for clascoterone). Clascoterone’s advantage is its potentially cleaner side-effect profile. For many patients, the two could eventually be used together.
Can I use clascoterone with minoxidil?
There is no pharmacological reason you could not. Minoxidil promotes growth via potassium channel activation; clascoterone blocks androgen-driven damage. They target different parts of the hair loss equation. Formal combination trial data is not available yet, but the mechanistic logic supports using them together.
What about pyrilutamide - is that better?
Pyrilutamide (KX-826) appears to be a stronger AR antagonist in vitro, and Kintor Pharma’s pivotal Phase III data showed +15.33 hairs/cm² from baseline at 24 weeks for the highest dose. However, it is not approved anywhere, has no long-term safety data from regulatory trials, and an earlier 24-week trial failed to beat placebo. Clascoterone has the regulatory advantage and a clearer path to market.
Cosmo Pharmaceuticals. Clascoterone 5% (Breezula) Phase 3 clinical trial results. 2025.
Kintor Pharmaceutical. KX-826 Phase III pivotal trial top line results. March 2026.
Olsen EA, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-385.
Kaufman KD, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589.
